|
|
|
| Clinical study of transcatheter arterial chemoembolization combined with Sorafenib in the treatment of primary hepatic carcinoma |
| BI Da-peng1 ZHANG Xiao-xiao2 |
1.The Sixth Ward,Tumor Hospital of Anshan City,Liaoning Province,Anshan114036,China;
2.The 12thWard,Tumor Hospital of Anshan City,Liaoning Province,Anshan114036,China |
|
|
|
|
Abstract Objective To evaluate the clinical efficacy of transcatheter arterial chemoembolization(TACE)combined with Sorafenib in the treatment of primary hepatic carcinoma.Methods One hundred and fourteen patients with advanced primary hepatic carcinoma admitted in Tumor Hospital of Anshan City from January 2009 to April 2011 were randomly divided into experimental group and control group,57 cases in each group.Patients of the experimental group were treated with TACE combined with Sorafenib,and patients of the control group were treated with TACE alone.The therapeutic effect,concentration of AFP,and Karnofsky score of the two groups were observed;adverse reaction,skin reaction and 5-year survival rate were observed.Results The total effective rate in the experimental group(73.68%)was significantly higher than that in the control group(49.12%)(P<0.01).After treatment,the AFP concentration and Karnofsky score of the two groups were significantly improved compared with before treatment,and the experimental group was better than the control group(P<0.01).During the treatment,there was no serious adverse reactions were observed in the two groups.The incidence of skin reaction in the experimental group(64.9%)was significantly higher than that in the control group(10.5%)(P<0.01).The 5 years survival rate of the patients in the trial group was higher than that in the control group(P<0.01).Conclusion The treatment of primary hepatic carcinoma with hepatic arterial chemoembolization combined with Sorafenib can achieve significant short-term effect.The changes of AFP concentration and Karnofsky score after treatment are improved significantly.The adverse effect is mild,long-term outcomes is satisfactory,is worthy of clinical promotion vigorously.
|
|
|
|
|
|
| [1] |
Jemal A，Siegel R，Xu J，et al.Cancer statistics，2010[J].CA Cancer J Clin，2011，61（2）：133-134.
|
| [2] |
周仁贵，周锡建，李相勇，等.索拉非尼联合化疗栓塞治疗晚期原发性肝癌的疗效分析[J].现代生物医学进展，2014， 14（13）：2494-2496.
|
| [3] |
杨明，罗克品，谢岳云，等.肝动脉化疗栓塞联合索拉菲尼治疗中晚期肝细胞癌[J].肝胆胰外科杂志，2013，25（4）：265-268.
|
| [4] |
Kudo M，Imanaka K，Chida N，et al.PhaseⅢstudy of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma[J].Eur J Cancer，2011，47（14）：2117-2127.
|
| [5] |
马丽丽，韩忠诚，柳江.肝动脉化疗栓塞术联合索拉菲尼治疗肝细胞肝癌的临床疗效与安全性评价[J].中国临床药理学杂志，2015，31（15）：1497-1499.
|
| [6] |
张玉山，高国生.经皮肝动脉化疗栓塞术联合索拉非尼治疗肝癌的疗效及不良反应研究[J].中国生化药物杂志，2014，34（7）：99-101.
|
| [7] |
Pinter M，Hucke F，Graziadei I，et al.Advanced-stage hepatocellular carcinoma：transarterial chemoembolization versus sorafenib[J].Radiology，2012，263（2）：590-599.
|
| [8] |
陈路锋，苏洪英，徐克，等.索拉非尼联合经肝动脉化疗栓塞术治疗原发性肝细胞癌的疗效和安全性[J].中国医学科学院学报，2014，36（33）：33-36.
|
| [9] |
谢佳杭，王久惠.索拉菲尼联合TACE治疗进展期原发性肝癌疗效及并发症分析[J].肿瘤预防与治疗，2015，28（3）：152-154.
|
| [10] |
刘文博.索拉菲尼联合肝动脉化疗栓塞治疗原发性肝癌的研究进展[J].山东医药，2014，54（44）：101-102.
|
| [11] |
徐艳霞，高炜，刘洁，等.索拉菲尼联合肝动脉栓塞化疗对晚期肝细胞癌患者的疗效[J].肿瘤药学，2015，5（5）：372-377.
|
| [12] |
Dufour JF，Hoppe H，Heim MH，et al.Continuous administrationofsorafenibincombinationwithtransarterial chemoembolization in patients with hepatocellular carcinoma：results of a phase I study[J].Oncologist，2010，15（11）：1198-1204.
|
| [13] |
唐大平，林如景，王学健，等.索拉非尼治疗中晚期肝细胞癌疗效及血清甲胎蛋白水平变化意义分析[J].疑难病杂志，2014，13（5）：451-455.
|
| [14] |
冯锐，刘芳，白义凤.索拉菲尼联合肝动脉栓塞化疗和氩氦刀消融治疗晚期肝癌的效果观察[J].中国综合临床，2014，30（7）：739-742.
|
| [16] |
吴金道，韩国勇，陆森，等.肝动脉栓塞化疗术联合索拉菲尼对比单纯介入术治疗原发性肝癌的临床观察[J].南京医科大学学报（自然科学版），2015，35（12）：1739-1742.
|
| [15] |
Kelley RK，Venook AP.Sorafenib in hepatocellular carcinoma：separating the hype from the hope[J].J Clin Oncol，2008，26（36）：5845-5848.
|
|
|
|
